Magnus Nakrem Lyngbakken1, Julia Brox Skranes1, James A de Lemos1, Ståle Nygård1, Håvard Dalen1, Kristian Hveem1, Helge Røsjø1, Torbjørn Omland2. 1. From Division of Medicine, Akershus University Hospital, Lørenskog, Norway (M.N.L., J.B.S., H.R., T.O.); Center for Heart Failure Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.N.L., H.R., T.O.); Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (J.A.d.L.); Bioinformatics Core Facility, Institute for Medical Informatics, Oslo University Hospital and University of Oslo, Oslo, Norway (S.N.); Department of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, and Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway (H.D.); K.G. Jebsen Center for Exercise in Medicine, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway (H.D.); and HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway (K.H.). 2. From Division of Medicine, Akershus University Hospital, Lørenskog, Norway (M.N.L., J.B.S., H.R., T.O.); Center for Heart Failure Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (M.N.L., H.R., T.O.); Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (J.A.d.L.); Bioinformatics Core Facility, Institute for Medical Informatics, Oslo University Hospital and University of Oslo, Oslo, Norway (S.N.); Department of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, and Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway (H.D.); K.G. Jebsen Center for Exercise in Medicine, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway (H.D.); and HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway (K.H.). torbjorn.omland@medisin.uio.no.
Abstract
BACKGROUND: Both tobacco smoking and circulating cardiac troponin I (cTnI) levels are associated with the risk of acute myocardial infarction, heart failure, and cardiovascular death. However, whether cTnI levels differ according to smoking status and whether smoking modifies the prognostic relationship between cTnI and outcomes remain unclear. METHODS: Using data from a large, population-based cohort, we assessed the association between smoking and cTnI and the impact of smoking on the associations between cTnI levels and the incidence of acute myocardial infarction, heart failure, and cardiovascular death. cTnI was measured with a high-sensitivity assay in 3824 never smokers, 2341 former smokers, and 2550 current smokers participating in the prospective observational HUNT Study (Nord-Trøndelag Health Study). All subjects were free from known prior cardiovascular disease and diabetes mellitus at baseline. RESULTS: The age of the participants ranged from 19 to 94 years; 55.5% were women. Current smokers exhibited significantly lower levels of cTnI (median, 2.9 ng/L; interquartile range, 2.0-4.1 ng/L) than never smokers (3.2 ng/L; interquartile range, 2.2-4.7 ng/L; P<0.001) and former smokers (3.4 ng/L; interquartile range, 2.3-5.0 ng/L; P<0.001). This association remained significant after adjustment for potential confounders (B=-0.098; 95% confidence interval, -0.129 to -0.068). We observed an association between increasing concentrations of cTnI and clinical end points in the total study cohort (adjusted hazard ratio per log unit increase in cTnI, 1.41; 95% confidence interval, 1.29-1.54). This association was attenuated for current smokers (hazard ratio, 1.17; 95% confidence interval, 0.98-1.40) and was significantly weaker than in never/former smokers (P for interaction=0.003). Prognostic accuracy, as assessed by C statistics, was significantly lower in current smokers than in never smokers (P<0.001). In addition, cTnI provided no incremental prognostic information to the Framingham Cardiovascular Disease risk score in current smokers (P=0.08). CONCLUSIONS: Current smoking is associated with lower concentrations of cTnI, suggesting that substances in tobacco smoke may affect cardiomyocyte injury. The association between cTnI levels and cardiovascular end points is stronger in never/former smokers than in current smokers, compatible with the theory that the detrimental cardiovascular impact of current smoking is mediated via mechanisms other than subclinical myocardial injury.
BACKGROUND: Both tobacco smoking and circulating cardiac troponin I (cTnI) levels are associated with the risk of acute myocardial infarction, heart failure, and cardiovascular death. However, whether cTnI levels differ according to smoking status and whether smoking modifies the prognostic relationship between cTnI and outcomes remain unclear. METHODS: Using data from a large, population-based cohort, we assessed the association between smoking and cTnI and the impact of smoking on the associations between cTnI levels and the incidence of acute myocardial infarction, heart failure, and cardiovascular death. cTnI was measured with a high-sensitivity assay in 3824 never smokers, 2341 former smokers, and 2550 current smokers participating in the prospective observational HUNT Study (Nord-Trøndelag Health Study). All subjects were free from known prior cardiovascular disease and diabetes mellitus at baseline. RESULTS: The age of the participants ranged from 19 to 94 years; 55.5% were women. Current smokers exhibited significantly lower levels of cTnI (median, 2.9 ng/L; interquartile range, 2.0-4.1 ng/L) than never smokers (3.2 ng/L; interquartile range, 2.2-4.7 ng/L; P<0.001) and former smokers (3.4 ng/L; interquartile range, 2.3-5.0 ng/L; P<0.001). This association remained significant after adjustment for potential confounders (B=-0.098; 95% confidence interval, -0.129 to -0.068). We observed an association between increasing concentrations of cTnI and clinical end points in the total study cohort (adjusted hazard ratio per log unit increase in cTnI, 1.41; 95% confidence interval, 1.29-1.54). This association was attenuated for current smokers (hazard ratio, 1.17; 95% confidence interval, 0.98-1.40) and was significantly weaker than in never/former smokers (P for interaction=0.003). Prognostic accuracy, as assessed by C statistics, was significantly lower in current smokers than in never smokers (P<0.001). In addition, cTnI provided no incremental prognostic information to the Framingham Cardiovascular Disease risk score in current smokers (P=0.08). CONCLUSIONS: Current smoking is associated with lower concentrations of cTnI, suggesting that substances in tobacco smoke may affect cardiomyocyte injury. The association between cTnI levels and cardiovascular end points is stronger in never/former smokers than in current smokers, compatible with the theory that the detrimental cardiovascular impact of current smoking is mediated via mechanisms other than subclinical myocardial injury.
Authors: Paul Welsh; David Preiss; Anoop S V Shah; David McAllister; Andrew Briggs; Charles Boachie; Alex McConnachie; Caroline Hayward; Sandosh Padmanabhan; Claire Welsh; Mark Woodward; Archie Campbell; David Porteous; Nicholas L Mills; Naveed Sattar Journal: Clin Chem Date: 2018-08-20 Impact factor: 8.327
Authors: Anna Fretz; John W McEvoy; Casey M Rebholz; Chiadi E Ndumele; Roberta Florido; Ron C Hoogeveen; Christie M Ballantyne; Elizabeth Selvin Journal: Am J Cardiol Date: 2017-11-24 Impact factor: 2.778
Authors: Christopher W Puleo; Colby R Ayers; Sonia Garg; Ian J Neeland; Alana A Lewis; Ambarish Pandey; Mark H Drazner; James A de Lemos Journal: Biomark Med Date: 2021-10-19 Impact factor: 2.851
Authors: Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-01 Impact factor: 4.733
Authors: Matthew Nayor; Meghan I Short; Humaira Rasheed; Honghuang Lin; Christian Jonasson; Qiong Yang; Kristian Hveem; Janine F Felix; Alanna C Morrison; Philipp S Wild; Michael P Morley; Thomas P Cappola; Mark D Benson; Debby Ngo; Sumita Sinha; Michelle J Keyes; Dongxiao Shen; Thomas J Wang; Martin G Larson; Ben M Brumpton; Robert E Gerszten; Torbjørn Omland; Ramachandran S Vasan Journal: Circ Heart Fail Date: 2020-05-15 Impact factor: 8.790
Authors: Nick S R Lan; Damon A Bell; Kieran A McCaul; Samuel D Vasikaran; Bu B Yeap; Paul E Norman; Osvaldo P Almeida; Jonathan Golledge; Graeme J Hankey; Leon Flicker Journal: J Am Heart Assoc Date: 2019-03-05 Impact factor: 5.501
Authors: Caroline Haig; David Carrick; Jaclyn Carberry; Kenneth Mangion; Annette Maznyczka; Kirsty Wetherall; Margaret McEntegart; Mark C Petrie; Hany Eteiba; Mitchell Lindsay; Stuart Hood; Stuart Watkins; Andrew Davie; Ahmed Mahrous; Ify Mordi; Nadeem Ahmed; Vannesa Teng Yue May; Ian Ford; Aleksandra Radjenovic; Paul Welsh; Naveed Sattar; Keith G Oldroyd; Colin Berry Journal: JACC Cardiovasc Imaging Date: 2018-07-18